In intubated patients without SARS, data regarding the risk-benefit ratio
of empirical anticoagulation strategies are currently insufficient. The consideration of
anticoagulation at doses intermediate between prophylactic and full therapeutic levels
in patients with SARS was informed by the team's prior
experience during the 2009 H1N1 pandemic; however, this approach has
not yet been evaluated in the present context.